文献速递白血病淋巴瘤

Hyper-CVAD联合奈拉滨治疗新诊断成人T细胞急性淋巴细胞白血病和T淋巴母细胞淋巴瘤

Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma.
PubMed 文献 · Am J Hematol · 2017-11-03

这项单臂2期研究评估了Hyper-CVAD联合奈拉滨在新诊断成人T-ALL/T-LBL中的安全性和疗效。共纳入67例患者(T-ALL 40例,T-LBL 26例),T-ALL和T-LBL的完全缓解率分别为87%和100%,3年完全缓解持续率和总生存率分别为66%和65%。与历史Hyper-CVAD数据相比,加用奈拉滨未带来生存获益。

要点

  • T-ALL和T-LBL完全缓解率分别为87%和100%。
  • 3-4级神经毒性不良事件发生于5例患者。
  • 与历史Hyper-CVAD数据相比,加用奈拉滨无生存获益。

核心结论

  • Hyper-CVAD联合奈拉滨在新诊断成人T-ALL/LBL中耐受良好且有活性,但与历史Hyper-CVAD数据相比未带来生存获益。

研究设计与样本

  • 单臂2期研究,纳入67例新诊断成人T-ALL/LBL患者(T-ALL 40例,T-LBL 26例)。
  • 诱导/巩固阶段接受8个周期Hyper-CVAD与高剂量甲氨蝶呤和阿糖胞苷交替, plus 2个周期奈拉滨650 mg/m2静脉每日×5天;随后30个月POMP维持化疗,其中第6和第7周期以额外2个周期奈拉滨替代。

主要发现

  • T-ALL完全缓解率为87%,T-LBL完全缓解率为100%。
  • 3-4级神经毒性不良事件见于5例患者。
  • 复发21例(31%),其中2例发生于异基因干细胞移植后。
  • 中位随访时间42.5个月,3年完全缓解持续率为66%,3年总生存率为65%。
  • 与历史Hyper-CVAD数据相比,加用奈拉滨无生存获益。

关键数值与推荐

  • 奈拉滨剂量为650 mg/m2静脉每日×5天。
  • Hyper-CVAD交替高剂量甲氨蝶呤和阿糖胞苷共8个周期。
  • POMP维持化疗持续30个月,第6和第7周期以奈拉滨替代。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nelarabine, a water soluble prodrug of 9-β-D-arabinofuranosylguanine (ara-G), is a T-cell specific purine nucleoside analogue. Given its activity in relapsed and refractory T acute lymphoblastic leukemia (T-ALL) and T lymphoblastic lymphoma (T-LBL), we sought to define its role in the frontline treatment of adult patients. Therefore, we conducted a single arm phase 2 study to determine the safety and efficacy of nelarabine in combination with hyper-CVAD in newly diagnosed patients. For induction/consolidation, patients received eight cycles of hyper-CVAD alternating with high-dose methotrexate and cytarabine plus two cycles of nelarabine given at a dose of 650 mg/m2 intravenously daily for 5 days. This was followed by thirty months of POMP maintenance chemotherapy with two additional cycles of nelarabine given instead of cycles 6 and 7 of POMP maintenance. Sixty-seven patients, including 40 with T-ALL and 26 with T-LBL, were enrolled. Complete response rates in both T-ALL and T-LBL were 87% and 100% respectively. Grade 3 to 4 neurotoxic adverse events were reported in 5 patients. There were 21 relapses (31%) including 2 after allogeneic stem cell transplantation. Median duration of follow-up was 42.5 months. The 3-year complete remission duration (CRD) and overall survival (OS) rates were 66% and 65%, respectively. Compared to our historic hyper-CVAD data, there was no survival benefit with the addition of nelarabine. In conclusion, hyper-CVAD plus nelarabine was well tolerated and active in the frontline treatment of adult T-ALL/LBL patients.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Abaza Y, M Kantarjian H, Faderl S, et al. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. Am J Hematol. 2017. PMID: 29047158. doi:10.1002/ajh.24947

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。